title: The management of hepatitis C.
abstract: Hepatitis C is a serious public health problem with more than 170 million chronic carriers worldwide. Although hepatitis C infection can be cured in up to 40% of patients, current treatment is not ideal and is associated with a wide spectrum of side effects and complications. Therefore, emerging evidence suggests that patients can receive tailored therapy based on their viral kinetic changes during treatment. With better knowledge of hepatitis C viral genome and life cycle, compounds so called ''Specifically Targeted Antiviral Therapy for HCV or STAT-C'' are under development. This review will discuss current therapies and recent advances in new therapies for hepatitis C.
authors.affiliation: Section of Hepatobiliary Diseases and Liver Transplantation, Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Florida Gainesville, FL, USA.
authors.forename: J J
authors.initials: JJ
authors.lastname: Pan
authors.forename: R J
authors.initials: RJ
authors.lastname: Firpi
mesh_terms: D005838:Genotype; D016174:Hepacivirus / Q000235:genetics; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D011480:Protease Inhibitors / Q000627:therapeutic use
chemical_list: D011480:Protease Inhibitors